Harmony Biosciences Reaffirms 2026 Wakix Revenue Outlook
Harmony Biosciences maintained its 2026 net revenue guidance for Wakix at $1.0B-$1.04B, Dow Jones Newswires reported in its latest update.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Harmony Biosciences reaffirmed its guidance for 2026 net revenue from Wakix at $1.0B-$1.04B.
Dow Jones Newswires reported the update. The company kept its previously stated outlook for revenue generated by Wakix unchanged.
why it matters
Reaffirming the guidance signals no change in the company’s expectations for Wakix revenue and may shape market sentiment toward HRMY shares.
instruments
sources
- Harmony Biosciences Reiterates 2026 Wakix Net Rev Guidance of $1.0B-$1.04B >HRMY — Dow Jones Newswires, 12 October 2026 at 11:02 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗